The Maureen Horton Lab conducts research on pulmonary fibrosis through the use of both preclinical models and human trials. Our studies have helped to develop novel, genetic, tissue-specific models of immune dysfunction, which have aided in defining the immune regulation of fibrosis and in the development of treatment strategies. We have used T-cell skewing immunotherapy to prevent and reverse chemical-induced lung fibrosis and have conducted clinical trials for idiopathic pulmonary fibrosis (IPF), which led to one of the first treatments that helped to improve quality of life in IPF patients.

Research in the Sonye Danoff Lab includes both basic and translational studies of lung fibrosis. We have explored topics such as the role of support measures and palliative care, pulmonary manifestations of Sjogren's syndrome, idiopathic inflammatory myopathies and the treatment of cough in idiopathic pulmonary fibrosis. Our research has also involved investigating the lung as a potential target for the immune reaction in myositis.

The Stephen Mathai Lab focuses its research on pulmonary medicine. We're particularly interested in scleroderma-associated pulmonary hypertension, pulmonary complications of connective tissue disease, idiopathic pulmonary fibrosis and pulmonary hypertension.